New hope for pancreatic cancer: targeted drug combo enters human trials
NCT ID NCT07444541
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shrinks tumors. About 84 participants will be enrolled, and treatment may last up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ANO31905 (a biologic drug) combined with chemotherapy (gemcitabine and nanoparticle albumin-bound paclitaxel)
What this could lead to
If it works, this could offer a new first-line treatment option for people with a specific type of advanced pancreatic cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 84 participants, so results are preliminary. The drug may cause serious side effects like cytokine release syndrome, and it may not work better than standard chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••